In an effort to maximize outcomes, recent expert guidelines recommend more-intensive vancomycin dosing schedules to maintain vancomycin troughs between 15 and 20 mg/liter. The widespread use of these more-intensive regimens has been associated with an increase in vancomycin-induced nephrotoxicity reports. The purpose of this systematic literature review is to determine the nephrotoxicity potential of maintaining higher troughs in clinical practice. All studies pertaining to vancomycin-induced nephrotoxicity between 1996 and April 2012 were identified from PubMed, Embase, Cochrane Controlled Trial Registry, and Medline databases and analyzed according to Cochrane guidelines. Of the initial 240 studies identified, 38 were reviewed, and 15 studies met the inclusion criteria. Overall, higher troughs (>15 mg/liter) were associated with increased odds of nephrotoxicity (odds ratio [OR], 2.67; 95% confidence interval [CI], 1.95 to 3.65) relative to lower troughs of <15 mg/liter. The relationship between a trough of >15 mg/liter and nephrotoxicity persisted when the analysis was restricted to studies that examined only initial trough concentrations (OR, 3.12; 95% CI, 1.81 to 5.37). The relationship between troughs of >15 mg/liter and nephrotoxicity persisted after adjustment for covariates known to independently increase the risk of a nephrotoxicity event. An incremental increase in nephrotoxicity was also observed with longer durations of vancomycin administration. Vancomycin-induced nephrotoxicity was reversible in the majority of cases, with short-term dialysis required only in 3% of nephrotoxic episodes. The collective literature indicates that an exposure-nephrotoxicity relationship for vancomycin exists. The probability of a nephrotoxic event increased as a function of the trough concentration and duration of therapy.
S
ince its discovery in the 1950s, vancomycin has been a mainstay of therapy for serious Staphylococcus aureus infections. Although vancomycin was a second-line therapy early in its life cycle, it emerged as a first-line agent for infections due to methicillin-resistant S. aureus (MRSA) in the 1970s (1) . Over the next several decades, its usage dramatically increased due to the explosion of MRSA in both the community and health care settings (2) (3) (4) . Despite the recent availability of alternative agents, vancomycin still remains the treatment of choice for serious MRSA infections (5) .
Despite its widespread use, there are growing concerns about the future role of vancomycin, particularly among patients who have invasive MRSA infections with vancomycin MICs of Ͼ1 mg/ liter (6). Although host-and pathogen-related factors have been implicated as a cause, suboptimal vancomycin dosing has been suggested as an alternative explanation for the poorer outcomes among these patients. To counteract some of these concerns and to maximize the likelihood of achieving a 24-h ratio of area under the curve to MIC (AUC/MIC) of greater than 400, expert guidelines now recommend more-intensive vancomycin dosing and maintenance of troughs between 15 mg/liter and 20 mg/liter for serious MRSA infections (7) (8) (9) .
The recommendation to maintain troughs between 15 and 20 mg/liter for serious MRSA infections has been widely integrated into clinical practice. Despite its adoption, there are (10) limited data to suggest that maintenance of vancomycin trough values between 15 and 20 mg/liter improves outcomes (8, 10) . Furthermore, the widespread use of the more-intensive vancomycin dosing schedules advocated by recent guidelines has been associated with increasing reports of vancomycin-induced nephrotoxicity. Nephrotoxicity is a longstanding, yet highly debated, adverse effect associated with vancomycin administration (1) . Initial reports of vancomycin-induced nephrotoxicity were largely attributed to impurities in the original formulation. Following modern fermentation methods and purification, nephrotoxicity was considered to be infrequent (5 to 7%) and reversible (1, 11, 12) . With increasing reports of vancomycin-induced nephrotoxicity in the "15-to 20-mg/liter" vancomycin trough era, there is a renewed interest in evaluating the relationship between vancomycin trough concentrations and incidence of nephrotoxicity (13) (14) (15) (16) . Although there are a few recent review articles on this topic, no group has attempted to quantify systematically the risk associated with increased vancomycin trough levels (17) (18) (19) . The purpose of this systematic literature review and meta-analysis is to determine the nephrotoxicity potential of maintaining higher troughs (Ͼ15 mg/ liter) in clinical practice.
MATERIALS AND METHODS
Search strategy and selection criteria. Studies were retrieved from the PubMed, Embase, Cochrane Controlled Trial Registry, and Medline databases from January 1995 to April 2012. Search terms included "vanco-mycin" in combination with "nephrotoxicity" or "renal toxicity" or "renal injury." References were also identified from the bibliographies of studies retrieved from the literature search. Studies written in languages other than English and those presented solely as abstracts at scientific conferences were not considered in this analysis.
Study selection. The abstracts of all studies were reviewed. A study was considered eligible for inclusion if the observed nephrotoxicity rates could be extracted and stratified by vancomycin troughs (Ͻ15 versus Ն15 mg/ liter). Studies in which vancomycin was administered by continuous infusion were excluded to ensure uniformity in vancomycin administration across studies. When data pertinent to our review were missing, authors were contacted (whenever possible) to provide further details.
Data extraction, outcomes, and data analysis. Data extracted from the identified studies included clinical setting, number of patients studied, inclusion and exclusion criteria, definitions of nephrotoxicity, and concomitant risk factors for nephrotoxicity (age, residence in intensive care unit [ICU] , severity of illness, and receipt of concomitant nephrotoxins as defined in each study). Additional information extracted included vancomycin treatment duration, vancomycin trough levels, and patient outcomes, if available.
Analyzed outcomes. The primary outcome was incidence of vancomycin nephrotoxicity among patients with high vancomycin troughs (Ն15 mg/liter) relative to those with low vancomycin troughs (Ͻ15 mg/ liter). Since the definition of nephrotoxicity varied slightly across the studies, the nephrotoxicity definition employed in the reviewed study was used in the primary outcome analysis. In addition to the primary analysis, several restricted analyses were performed. These restricted analyses included studies (i) that were limited to adults (Ն18 years of age), (ii) that evaluated the relationship between initial trough values (high versus low) and nephrotoxicity, (iii) that examined the risk of nephrotoxicity across more demarcated trough strata (Ͻ10, 10 to 15, 15 to 20, and Ͼ20 mg/ liter), (iv) that assessed the effect of duration of therapy on incidence of nephrotoxicity, and (v) that only had authors with no declared conflicts of interest with pharmaceutical companies. Secondary outcomes examined included mortality, hospital length of stay, reversibility of the nephrotoxicity, and need for renal replacement therapy following a nephrotoxic event.
Data analysis and statistical methods. Data analysis was performed using Review Manager (RevMan), version 5.1 (The Cochrane Collaboration, 2011, The Nordic Cochrane Centre, Copenhagen). Odds ratios (OR) and 95% confidence intervals (CI) for dichotomous variables were calculated. Meta-analysis was performed using fixed-effects models, unless significant heterogeneity was observed, in which case random-effects models were used. Heterogeneity was assessed using the chi-square test with the extent of inconsistency assessed using I 2 statistics. A P value of 0.05 was regarded as significant.
RESULTS
Our literature search identified 240 studies. Of the 240 studies, 38 studies were reviewed and 15 were included in the meta-analysis (8, (13) (14) (15) (16) . Twenty-three studies were excluded for the following reasons: nephrotoxicity data were not presented by vancomycin trough strata (Ͻ15 versus Ն15 mg/liter; 20 studies) (16, 20, 24, 25, 27-29, 33-35, 37, 41, 42, 44-47, 49, 52) ; nephrotoxicity data were stratified by alternative vancomycin trough strata (Ͻ10 versus Ն10 mg/liter; 1 study) (26) ; the study was a case report (1 study) (40) ; and vancomycin was administered as a continuous infusion (2 studies) (14, 48) .
The remaining 15 studies were included in the meta-analysis (Table 1) (8, 13, 15, 21-23, 30-32, 36, 38, 39, 43, 50, 51) . Of these, 14 studies were conducted with adults and 1 involved children (38) ( Table 1 ). The average trough value over the duration of therapy was examined in 6 studies (13, 30, 38, 39, 43, 50) , and the initial trough value was considered in 8 studies (8, 15, 21-23, 32, 36, 51) . Although timing differed between studies, most initial trough levels were obtained at the time or shortly after steady state was achieved (i.e., after the 3rd dose) but not greater than 4 days into therapy (Table 2 ). In patients with multiple levels during this initial period, the highest trough (22, 36) or the average trough (21) was used to define the trough exposure in the parent analysis. Four studies categorized vancomycin into more precisely defined trough strata (8, 22, 36, 50) , while four studies provided data for nephrotoxicity as a function of duration of vancomycin therapy (13, 15, 39, 43) .
Nephrotoxicity. The incidence of nephrotoxicity varied between studies from 5% to 43%. On average, nephrotoxicity occurred between 4.3 and 17 days after initiation of vancomycin therapy (13, 21, 22, 30, 32, 36, 38, 39, 43, 51) . The definition of nephrotoxicity was identical (increase in serum creatinine [S CR ] of 0.5 mg/dl, equivalent to 44.2 mol/liter or 50% from baseline on 2 consecutive measurements) in all but three studies ( Table 1 ). Of the three dissimilar studies, one used the Acute Kidney Injury Network classification of nephrotoxicity (23), one employed the Risk-Injury-Failure-Loss-End-stage-renal disease (RIFLE) classification of nephrotoxicity (39) , and one used a nonstandardized definition of nephrotoxicity (increase in S CR by 20% from baseline or Ն110 mol/liter or a decrease of creatinine clearance by Ͻ0.7 ml/s, equivalent to 42 ml/min) (31) .
In the primary analysis, higher troughs (Ն15 mg/liter) were associated with increased nephrotoxicity (OR, 2.67; 95% CI, 1.95 to 3.65; P Ͻ0.01) relative to low troughs (Ͻ15 mg/liter) (Fig. 1) . The results did not change considerably when the analysis was restricted to adult patients (OR, 2.54; 95% CI, 1.84 to 3.50; P Ͻ 0.01) (38) . The odds of nephrotoxicity among patients with troughs of Ն15 mg/liter remained increased (OR, 3.12; 95% CI, 1.81 to 5.37; P Ͻ 0.01) when the data were limited to studies that examined initial vancomycin trough values (8, 15, 21-23, 32, 36, 51) (Fig. 2) . In addition, troughs of Ն15 mg/liter remained significantly associated with nephrotoxicity when articles (8, 13, 21, 22, 30, 36, 43) in which authors declared potential conflicts of interests with pharmaceutical companies were excluded (OR, 2.84; 95% CI, 1.65 to 4.87; P Ͻ 0.01).
Only four studies provided nephrotoxicity rates as a function of incremental vancomycin trough values that confirmed the presence of an exposure-toxicity gradient (8, 22, 36, 50) (Fig. 3 ). All three found the highest rates of nephrotoxicity among patients with troughs of Ͼ20 mg/liter and the lowest rates among patients with troughs of Ͻ10 mg/liter. Two of the four studies found similar risks of nephrotoxicity between patients with troughs of 15 to 20 mg/liter and 10 to 15 mg/liter. In studies in which the duration of vancomycin therapy was analyzed, an incremental increase in nephrotoxicity (6% to 45%) was noted with longer durations (7 to 14 days) of therapy relative to shorter durations (Table 2) .
Three studies stratified baseline clinical characteristics by high (Ն15 mg/liter) and low (Ͻ15 mg/liter) vancomycin troughs (13, 30, 38) . A number of nephrotoxicity risk factors (e.g., increased severity of illness, receipt of concomitant nephrotoxins, and source of infection) were more pronounced in patients with high troughs than in those with low troughs. Patients in the ICU (OR, 2.57; 95% CI, 1.44 to 4.58; P Ͻ 0.01) were more likely to develop vancomycin-induced nephrotoxicity than were patients in non-ICU wards (Fig. 4) . Conversely, patients receiving concomitant nephrotoxins (OR, 3.30; 95% CI, 1.30 to 8.39; P ϭ 0.01) were more likely to develop vancomycin-induced nephrotoxicity than were patients who did not receive nephrotoxins (Fig. 5 ). These findings, however, were not uniform across studies. To adjust for potential confounders, several groups performed multivariate analyses (15, 21, 22, 36, 38, 39, 43) . In five of the seven studies, high vancomycin troughs (Ն15 mg/liter) remained an independent predictor of nephrotoxicity (Table 2) . Renal and clinical outcomes. In studies that reported on the clinical course of patients with vancomycin-induced nephrotoxicity, S CR levels returned to baseline or below predefined toxicity thresholds despite continuation of vancomycin in a substantial proportion of cases (35% to 46%) (36, 38, 43) . In situations where vancomycin was discontinued, most episodes (44% to 75%) were reported to resolve within a week or less (15, 38, 39, 43, 51) . In contrast, one study reported more-prolonged renal injury with S CR levels remaining toxic (Ն50% of baseline value) for Ն7 days in over 50% of episodes (36) . Short-term dialysis was required in a minority of patients (3%; 6 of 192 patients), and no patient was reported to require long-term dialysis (26, 36, 38, 43, 51) . Nephrotoxicity was associated with increased overall mortality (39) and prolonged hospital (8, 39) and ICU (22) lengths of stay.
Heterogeneity and publication bias. There was significant heterogeneity between the studies with different patient populations studied, nephrotoxicity definitions used, durations of vancomycin treatment required for inclusion, and measurements of trough level used in the analyses. As such, the random-effects model was required in all analyses.
DISCUSSION
The collective findings of this systematic review strongly suggest that adherence to the vancomycin trough recommendations in recent expert guidelines may result in an elevated risk of vancomycin-induced nephrotoxicity. Overall, maintaining troughs in excess of 15 mg/liter was found to substantially increase the risk of a nephrotoxic event (Fig. 2) . The relationship between troughs of Ն15 mg/liter and nephrotoxicity persisted when the analyses were restricted to studies that examined initial trough values. Interestingly, data from 4 of the 15 studies suggest that a trough-toxicity gradient exists, with the greatest risk observed among individuals with troughs of Ͼ20 mg/liter (Fig. 3) . The probability of a nephrotoxic event was also found to increase as a function of treatment duration, with most episodes occurring after 7 days of therapy. Lastly, data, albeit limited, may be applicable to children.
While the association between vancomycin trough and nephrotoxicity was largely uniform across studies, the incidence of vancomycin-induced nephrotoxicity was highly variable. Nephrotoxicity rates ranged between 5% and 43% and were highly dependent on the population evaluated. Not surprisingly, the highest nephrotoxicity rates were observed in studies that included a high percentage of critically ill patients that resided in the ICU and received concomitant nephrotoxins. It is well known that these populations have an elevated baseline risk of nephrotoxicity, independent of vancomycin exposure. While this suggests that vancomycin may not be responsible for the observed toxicity rates, a high vancomycin trough, Ͼ15 mg/liter, was still independently associated with a higher odds of nephrotoxicity in most studies that accounted for these variables in a multivariate analysis. Together, these findings imply that high vancomycin troughs augment the risk of nephrotoxicity, especially in the presence of conditions known to be independently associated with nephrotoxicity. Conversely, these medical factors likely affect the vanco- mycin trough concentration threshold at which the risk of nephrotoxicity is likely to increase. The multifactorial nature of vancomycin-induced nephrotoxicity is best highlighted by the findings of two recent randomized clinical trials (50, 53) . In the ceftaroline fosamil versus vancomycin/aztreonam for complicated skin and skin structure infections (cSSSI) clinical trial, the incidence of nephrotoxicity in the vancomycin arm was 1.3%, only 0.9% greater than in the ceftaroline arm (53) . Of note, patients in this study rarely resided in the ICU, generally had troughs of Ͻ10 mg/liter, and typically received therapy for Ͻ10 days. In comparison, the incidence of nephrotoxicity was 9.6% greater with vancomycin than with linezolid in the recent phase IV vancomycin versus linezolid for nosocomial MRSA pneumonia clinical trial. In this study, patients were generally in poorer health (the mean Acute Physiology and Chronic Health Evaluation [APACHE II] score was 17.6), with 64% of patients requiring ventilation (50) .
While the incidence of nephrotoxicity is concerning, it appears to be largely reversible in the majority of cases following vancomycin discontinuation (36, 38, 43, 51) . Short-term dialysis was required in only approximately 3% of cases, and no patient needed long-term dialysis. All patients who required dialysis also received concomitant nephrotoxins (43) . This finding supports the notion that certain clinical factors augment the severity of vancomycin-induced renal impairment. Although vancomycininduced nephrotoxicity was generally reversible, it should be noted that the nephrotoxic events were associated with increased lengths of stay and poorer outcomes (39, 54) .
Several issues should be considered when interpreting these results. First, it is a challenge to completely establish that exposure-nephrotoxicity relationships exist for drugs that are renally eliminated. Since vancomycin is eliminated predominantly by glomerular filtration, a decrease in renal function from any cause will increase vancomycin serum concentrations (13, 15) . Cognizant of this, we performed an analysis limited to studies that examined only initial troughs. The odds of nephrotoxicity remained increased, at 3.12 (95% CI, 1.81 to 5.37; P Ͻ 0.01) for patients attaining initial trough levels of Ն15 mg/liter (8, 13, 21, 22, 30, 36, 43) . The presence of a vancomycin trough-nephrotoxicity relationship is further substantiated when one considers that most 
FIG 2
Forest plot (using Mantel-Haenszel [M-H] analysis) of events denoting nephrotoxicity associated with vancomycin, comparing rates for initial trough levels of Ն15 mg/dl and Ͻ15 mg/dl. Squares indicate point estimates, and the size of the square indicates the weight of each study. All initial trough levels were obtained at the time or shortly after steady state was achieved (i.e., after the 3rd dose) and not greater than 4 days into therapy (see Table 2 for more details). van Hal et al. nephrotoxic events occurred after 7 days of therapy (13, 15, 39, 43) . This exposure-toxicity relationship is biologically plausible and supported by recent animal and human data that suggest vancomycin acts as an oxidative stressor in proximal renal tubular cells (55) (56) (57) (58) (59) (60) (61) .
Second, the results of the analysis that categorized vancomycin into more precisely defined trough strata (Ͻ10, 10 to 15, 15 to 20, and Ͼ20 mg/liter) suggest that vancomycin-induced nephrotoxicity is similar among patients with troughs between 10 and 20 mg/liter and greatest among patients with troughs in excess of 20 mg/liter. Due to the small demarcation in trough values between 10 to 15 and 15 to 20 mg/liter, there was a high potential for vancomycin stratum misclassification error, especially as these data are derived from retrospective cohort studies. While it is possible that vancomycin trough values of Ͼ20 mg/liter may be driving the nephrotoxicity in the Ͼ15-mg/liter strata, caution should be exercised before drawing definitive conclusions from these data (8, 22, 36, 50) . Until more data are available to adequately define the vancomycin exposure-toxicity curve, clinicians should rely on the collective results of the 15 studies included in this meta-analysis, which suggest that an augmented risk of toxicity occurs in individuals with troughs of Ͼ15 mg/liter (8, 13-15, 21-23, 30-32, 36, 38, 39, 43, 48, 50, 51) .
Third, it was difficult to fully quantify the role of concomitant nephrotoxins in the observed results. It is quite possible that the role of concomitant nephrotoxins may have been underestimated. The number of concomitant nephrotoxins listed in each study varied, and some studies provided only examples of nephrotoxic agents rather than an exhaustive list (8, 36) . No data on the relationship between the number of concurrent nephrotoxins and observed nephrotoxicity results were provided. Although definitions of concomitant use were similar across all studies except one (31), the effects of duration and timing of concomitant nephrotoxins on vancomycin-associated nephrotoxicity were not quantifiable.
Fourth, we could not exclude the presence of publication bias; positive studies are more likely to be published than negative ones. In addition, a targeted analysis taking into account all confounders was not possible; this limited the ability of this meta-analysis to definitively establish the presence of a causal relationship. As most studies included were retrospective observational cohorts, treat-
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Incidence of vancomycin nephrotoxicity with rising trough levels (8, 22, 36, 50) . ment selection bias and management decisions with respect to dosage adjustments could not be analyzed.
In conclusion, the findings from this systematic literature review strongly suggest that a relationship exists between the vancomycin trough value and nephrotoxicity. Patients with vancomycin troughs in excess of 15 mg/liter were found to have a greater risk of nephrotoxicity than did patients with troughs of Ͻ15 mg/ liter. The incidence of toxicity increased as a function of therapy duration, with the highest rates observed among critically ill individuals that resided in the ICU and received concomitant nephrotoxins. These observed results have important clinical implications and suggest that initial trough concentrations can serve as a prognostic indicator for nephrotoxicity and to identify patients that require careful monitoring. Based on collective findings, clinicians should intently monitor the renal function of patients receiving vancomycin, especially those patients being maintained at a trough value in excess of 15 mg/liter. Unfortunately, data on practical management decisions with respect to how and when to adjust the dose or cease vancomycin therapy remain lacking, and these issues require urgent study.
